Hyperfine (HYPR) Asset Writedowns and Impairment (2021)

Hyperfine (HYPR) posted Asset Writedowns and Impairment of $56000.0 for Q4 2021, up 500.0% on a QoQ basis from -$14000.0 in Q3 2021.

Hyperfine (HYPR) Asset Writedowns and Impairment (2021) Analysis & Trends

Hyperfine's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $56000.0 for Q4 2021.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $56000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $56000.0 (changed N/A YoY) and the FY2021 annual result came in at $75000.0, down 64.79% from the prior year.
Asset Writedowns and Impairment was $56000.0 for Q4 2021 at Hyperfine, up from -$14000.0 in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $75000.0 in Q1 2021 and bottomed at -$42000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Hyperfine	92.81 Mn	51.53 Mn	1.98 Mn

Download Data